Chronic corticosterone treatment impairs Leydig cell 11beta-hydroxysteroid dehydrogenase activity and LH-stimulated testosterone production.
The effects of excess corticosterone on luteinizing hormone (LH)-stimulated Leydig cell testosterone production and activity of 11beta-HSD was studied. Adult male rats (200-250 g body weight) were treated with corticosterone-21-acetate (2 mg/100 g body weight, i.m., twice daily) for 15 days. Another set of rats was treated with corticosterone (dose as above) plus LH (ovine LH 100 microg/kg body weight, s.c., daily) for 15 days. Corticosterone administration significantly increased serum and testicular interstitial fluid (TIF) corticosterone but decreased testosterone levels. Administration of LH with corticosterone partially prevented the decrease in serum and TIF testosterone. The oxidative activity of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) was significantly decreased in Leydig cells of rats treated with corticosterone alone and in combination with LH. The direct effect of corticosterone on Leydig cell steroidogenic potency was also studied in vitro. Addition of corticosterone to Leydig cell culture showed a dose dependent effect on LH-stimulated testosterone production. Corticosterone at 50 and 100 ng/ml did not alter LH-stimulated testosterone production, but at high doses (200-400 ng/ml), decreased basal and LH-stimulated testosterone production. Basal and LH-stimulated cAMP production was not altered by corticosterone in vitro. It is concluded from the present study that elevated levels of corticosterone decreased the oxidative activity of 11beta-HSD and thus resulting in impaired Leydig cell steroidogenesis and the inhibitory effects of corticosterone on testosterone production appear to be mediated through inhibition of LH signal transduction at post-cAMP level.
Sankar
B R
BR
Department of Endocrinology, Dr. ALM P.G. Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, India.
Maran
R R
RR
Sudha
S
S
Govindarajulu
P
P
Balasubramanian
K
K
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D000818:Animals; D002478:Cells, Cultured; D003345:Corticosterone / Q000097:blood / Q000494:pharmacology*; D000242:Cyclic AMP / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005110:Extracellular Space / Q000378:metabolism; D006913:Hydroxysteroid Dehydrogenases / Q000378:metabolism*; D066298:In Vitro Techniques; D007985:Leydig Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D007986:Luteinizing Hormone / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013739:Testosterone / Q000096:biosynthesis*
D013739:Testosterone; D007986:Luteinizing Hormone; D000242:Cyclic AMP; D006913:Hydroxysteroid Dehydrogenases; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D003345:Corticosterone